CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 12, 2025, at 2:00 PM ET.

The presentation will be available via webcast, accessible through the company's investor relations website. During the conference, which runs from August 12-14, 2025, management will also conduct one-on-one meetings with investors.

News Market Reaction – CRVO

+7.72%

2 alerts

+7.72% News Effect

-10.7% Trough Tracked

+$6M Valuation Impact

$89M Market Cap

0.3x Rel. Volume

On the day this news was published, CRVO gained 7.72%, reflecting a notable positive market reaction. Argus tracked a trough of -10.7% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $89M at that time.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45^th Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025.

Presentation Details
Format: Fireside Chat
Date: Tuesday, August 12, 2025
Time: 2:00 PM ET
Webcast Link: https://wsw.com/webcast/canaccord108/crvo/2537558

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b trial in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
Investors@cervomed.com
617-430-7579

FAQ

When is CervoMed (NASDAQ:CRVO) presenting at the Canaccord Genuity Conference?

CervoMed will present in a fireside chat on Tuesday, August 12, 2025 at 2:00 PM ET at the Canaccord Genuity Growth Conference in Boston.

How can investors access CervoMed's (CRVO) Canaccord conference presentation?

Investors can access the fireside chat webcast through two options: directly via wsw.com/webcast/canaccord108/crvo/2537558 or through the Investor section of CervoMed's website at cervomed.com.

What is CervoMed's (CRVO) main business focus?

CervoMed is a clinical stage company that focuses on developing treatments for age-related neurologic disorders.

What type of meetings will CervoMed (CRVO) conduct at the Canaccord conference?

CervoMed management will participate in a fireside chat presentation and hold one-on-one meetings with investors during the conference.